In August 2014, huge batches of the Eye Mo brand were pulled from the market at the request of the Philippines’ Food and Drug Administration (FDA). The reason was that the brand owner, GlaxoSmithKline Philippines Inc, did not comply with the Good Manufacturing Practice (GMP) released by the Italian Medicines Agency for the brand’s active ingredient, Tetrahydrozoline HCL. Stocks of Eye Mo branded eye drops in different variants were no longer being replenished as of early 2015. Thus, in 2016, no...
Euromonitor International's Eye Care in Philippines report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2011-2015, allowing you to identify the sectors driving growth. Forecasts to 2020 illustrate how the market is set to change.
Product coverage: Allergy Eye Care, Standard Eye Care.
Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.
Why buy this report?
Get a detailed picture of the Eye Care market;
Pinpoint growth sectors and identify factors driving change;
Understand the competitive environment, the market’s major players and leading brands;
Use five-year forecasts to assess how the market is predicted to develop.
Euromonitor International has over 40 years' experience of publishing market research reports, business reference books and online information systems. With offices in London, Chicago, Singapore, Shanghai, Vilnius, Dubai, Cape Town, Santiago, Sydney, Tokyo and Bangalore and a network of over 800 analysts worldwide, Euromonitor International has a unique capability to develop reliable information resources to help drive informed strategic planning.